Abstract
The number of patients with colorectal cancer on maintenance hemodialysis has been increasing. Chemotherapy schedules commonly used in colorectal cancer necessitate dose adjustment and appropriate timing relative to the hemodialysis sessions. Herein, we report the case of a 77-year-old man with RAS wild-type metastatic colonic cancer who was undergoing hemodialysis. Although this patient received the FOLFOX regimen for prevention of recurrence after resection of a hepatic metastasis, he developed multiple lung metastases. Panitumumab, a fully human IgG2 monoclonal anti-EGFR antibody, was administered in combination with the FOLFIRI regimen. Although the doses of cytotoxic chemotherapeutic agents were adequately reduced to avoid side effects, panitumumab was used without dose adjustment throughout the course. Computed tomography showed a partial response of the lung metastases to the EGFR- targeting chemotherapy. This case report demonstrates the feasibility, efficacy, and acceptable toxicity of biweekly panitumumab-based chemotherapy in patients undergoing hemodialysis.
